Department of Pharmacognosy, School of Pharmacy, College of Health Sciences, Mekelle University, P.O.Box 1871, Mekelle, Ethiopia.
Department of Pharmacy, College of Medicine and Health Sciences, Adigrat University, P.O.Box 50, Adigrat, Ethiopia.
BMC Complement Altern Med. 2019 Aug 7;19(1):206. doi: 10.1186/s12906-019-2622-5.
About 425 million adults had diabetes mellitus globally in 2017. Type 2 diabetes accounts for the enormous majority of diabetes cases and it is gradually growing which is predicted to increase by 48% in 2045. Imbalanced cellular carbohydrate and lipid metabolism cause an increase in postprandial blood glucose level which eventually leads to the onset and progression of type 2 diabetes mellitus. The lack of effective and safe carbohydrate hydrolyzing enzyme inhibitors contributes to the increasing prevalence. Thus, this study was targeted to assess the α-amylase inhibitory potential of isolates obtained from Aloe megalacantha Baker and Aloe monticola Reynolds, which are among the commonly used folkloric remedies for the management of diabetes mellitus.
The α-amylase inhibitory effect of Aloe megalacantha Baker and Aloe monticola Reynolds were evaluated using the 3,5-dinitro salicylic acid method. 2, 2-Diphenyl-2-picrylhydrazyl free radical scavenging property was also used to test the antioxidant effect of both plants. Results were analysed using GraphPad Prism software version 8.
The more polar isolates (AM and AG) were possessed stronger α-amylase inhibition activity than the leaves latex and the other strains (AM and AG). Leaf latex of A. megalacantha, AM, AM, leaf latex of A. monticola, AG, and AG were found to have an IC value of 74.76 ± 1.98, 37.83 ± 3.31, 96.75 ± 1.98, 78.10 ± 1.88, 56.95 ± 1.88 and 64.03 ± 3.60 μg/mL, respectively (P < 0.001). The leaf latexes of A. megalacantha and A. monticola showed a significant (P < 0.001) free radical hunting property with an IC value of 890.1 ± 1.73 and 597.5 ± 2.02 μg/mL, respectively.
Hence, the outcomes of the present investigation partly justify the acclaimed use of Aloe megalacantha and Aloe monticola for the treatment of diabetes.
2017 年，全球约有 4.25 亿成年人患有糖尿病。2 型糖尿病占糖尿病病例的绝大多数，且其发病率正在逐渐上升，预计到 2045 年将增长 48%。细胞碳水化合物和脂质代谢失衡导致餐后血糖水平升高，最终导致 2 型糖尿病的发生和发展。缺乏有效和安全的碳水化合物水解酶抑制剂是导致这种情况的原因之一。因此，本研究旨在评估从大芦荟 Baker 和大花芦荟 Reynolds 中分离得到的化合物对 α-淀粉酶的抑制潜力，这两种植物是治疗糖尿病的常用民间疗法之一。
采用 3,5-二硝基水杨酸法评估大芦荟 Baker 和大花芦荟 Reynolds 的 α-淀粉酶抑制作用。还使用 2,2-二苯基-2-苦基肼自由基清除法来测试这两种植物的抗氧化作用。结果使用 GraphPad Prism 软件版本 8 进行分析。
极性更强的分离物（AM 和 AG）比叶乳胶和其他菌株（AM 和 AG）具有更强的 α-淀粉酶抑制活性。大芦荟的叶乳胶、AM、AM、大花芦荟的叶乳胶、AG 和 AG 的 IC 值分别为 74.76 ± 1.98、37.83 ± 3.31、96.75 ± 1.98、78.10 ± 1.88、56.95 ± 1.88 和 64.03 ± 3.60 μg/mL（P < 0.001）。大芦荟和大花芦荟的叶乳胶表现出显著的（P < 0.001）自由基清除活性，IC 值分别为 890.1 ± 1.73 和 597.5 ± 2.02 μg/mL。
因此，本研究的结果部分证实了大芦荟和大花芦荟用于治疗糖尿病的传统用途。
